###begin article-title 0
Activin Signaling in Microsatellite Stable Colon Cancers Is Disrupted by a Combination of Genetic and Epigenetic Mechanisms
###end article-title 0
###begin p 1
Conceived and designed the experiments: BJ AG. Performed the experiments: BJ JG EC JC JL AA PS DRR JS SKS AG. Analyzed the data: BJ JG EC JC JL PS KM JS SKS AG. Wrote the paper: BJ KM RB AG JMC. Statistical Support: KM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
Activin receptor 2 (ACVR2) is commonly mutated in microsatellite unstable (MSI) colon cancers, leading to protein loss, signaling disruption, and larger tumors. Here, we examined activin signaling disruption in microsatellite stable (MSS) colon cancers.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR1</italic>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
Fifty-one population-based MSS colon cancers were assessed for ACVR1, ACVR2 and pSMAD2 protein. Consensus mutation-prone portions of ACVR2 were sequenced in primary cancers and all exons in colon cancer cell lines. Loss of heterozygosity (LOH) was evaluated for ACVR2 and ACVR1, and ACVR2 promoter methylation by methylation-specific PCR and bisulfite sequencing and chromosomal instability (CIN) phenotype via fluorescent LOH analysis of 3 duplicate markers. ACVR2 promoter methylation and ACVR2 expression were assessed in colon cancer cell lines via qPCR and IP-Western blots. Re-expression of ACVR2 after demethylation with 5-aza-2'-deoxycytidine (5-Aza) was determined. An additional 26 MSS colon cancers were assessed for ACVR2 loss and its mechanism, and ACVR2 loss in all tested cancers correlated with clinicopathological criteria.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
Of 51 MSS colon tumors, 7(14%) lost ACVR2, 2 (4%) ACVR1, and 5(10%) pSMAD2 expression. No somatic ACVR2 mutations were detected. Loss of ACVR2 expression was associated with LOH at ACVR2 (p<0.001) and ACVR2 promoter hypermethylation (p<0.05). ACVR2 LOH, but not promoter hypermethylation, correlated with CIN status. In colon cancer cell lines with fully methylated ACVR2 promoter, loss of ACVR2 mRNA and protein expression was restored with 5-Aza treatment. Loss of ACVR2 was associated with an increase in primary colon cancer volume (p<0.05).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
Only a small percentage of MSS colon cancers lose expression of activin signaling members. ACVR2 loss occurs through LOH and ACVR2 promoter hypermethylation, revealing distinct mechanisms for ACVR2 inactivation in both MSI and MSS subtypes of colon cancer.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 158 209 158 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">transforming growth factor &#946; receptor 2 (TGFBR2)</italic>
###xml 214 245 211 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">activin type 2 receptor (ACVR2)</italic>
###xml 245 248 242 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Carethers1">[1]</xref>
###xml 249 252 246 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Chung1">[3]</xref>
###xml 344 350 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 375 378 372 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Grady1">[4]</xref>
###xml 526 529 520 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Eppert1">[5]</xref>
###xml 530 533 524 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Takagi1">[7]</xref>
Colon cancers with high frequency microsatellite instability (MSI-H) are associated with mutations in several genes with coding repetitive sequences, such as transforming growth factor beta receptor 2 (TGFBR2) and activin type 2 receptor (ACVR2)[1]-[3]. Microsatellite stable (MSS) colon cancers have intact DNA mismatch repair, but may harbor TGFBR2 kinase domain mutations [4]. Other components of the TGFbeta canonical signaling cascade, such as SMAD2 and SMAD4, are specifically inactivated in a minority of colon cancers [5]-[7]. Systematic inactivation of TGFbeta's sister pathway, activin, has not been fully elucidated in MSS colon cancers.
###end p 11
###begin p 12
###xml 99 102 96 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Chen1">[8]</xref>
###xml 349 352 343 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Lee1">[9]</xref>
Activin is a member of the TGFbeta superfamily that regulates cell differentiation in many tissues [8]. Similar to TGFbeta, activin utilizes two cell surface receptors, activin receptor 1 (ACVR1) and activin receptor 2 (ACVR2), followed by SMAD activation. Another type 2 receptor, ACVR2B, cannot substitute for the functions and signaling of ACVR2 [9].
###end p 12
###begin p 13
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 68 72 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Mori1">[10]</xref>
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Hempen1">[11]</xref>
###xml 118 119 118 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 278 282 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Deacu1">[13]</xref>
###xml 336 341 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 428 431 428 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung3">[14]</xref>
###xml 579 582 579 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 592 598 592 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 631 634 631 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Grady1">[4]</xref>
ACVR2 was found mutated in the majority of MSI-H colorectal cancers [10], [11], primarily due to a frameshift in the A8 tract of exon 10. Restoration of activin signaling and growth suppression occur in response to ACVR2 complementation in ACVR2-mutant colon cancer cells [12], [13]. We have previously demonstrated a high frequency of ACVR2 mutations in MSI-H colon cancers in conjunction with loss of ACVR2 protein expression [2] and association with larger colon tumors and poorer histologic grade [14]. Also, we found a subset of MSS colon cancers that lost ACVR2 expression [2], akin to TGFBR2 loss found in MSS colon cancers [4].
###end p 13
###begin p 14
###xml 426 431 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 445 450 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 634 639 631 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
In this study, we explored activin signaling pathway disruption and possible mechanisms in primary MSS colon cancer specimens and colon cancer cells. We found that loss of ACVR2 expression occurs in a subset of MSS tumors, which is often associated with retained pSMAD2, the next downstream effector of both TGFbeta and activin signaling. Unlike that of TGFBR2, ACVR2 loss in MSS tumors occurs through a combination of LOH at ACVR2 and distinct ACVR2 promoter methylation, but not genetic mutation. In colon cancer cell lines, mechanisms for ACVR2 loss also segregate according to microsatellite status, with MSI-H cell lines showing ACVR2 polyadenine tract mutation and MSS colon cancer cells demonstrating promoter hypermethylation. Thus we show that disruption of activin signaling occurs in MSI and MSS colon cancers by distinct mechanisms, revealing activin signaling as an important target in the two most common genomic subtypes of colon cancer.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
Activin Signaling Pathway Members Are Targeted for Inactivation in Subsets of Primary MSS Colon Cancers
###end title 16
###begin p 17
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-SatiaAbouta1">[15]</xref>
###xml 489 493 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Satia1">[16]</xref>
###xml 586 605 586 605 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1AB, top row</bold>
###xml 586 605 586 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g001"><bold>Figure 1AB, top row</bold></xref>
###xml 669 691 669 691 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1CD, middle row</bold>
###xml 669 691 669 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g001"><bold>Figure 1CD, middle row</bold></xref>
###xml 826 848 826 848 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1EF, bottom row</bold>
###xml 826 848 826 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g001"><bold>Figure 1EF, bottom row</bold></xref>
###xml 924 931 924 931 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 924 931 924 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t001"><bold>Table 1</bold></xref>
###xml 561 568 <span type="species:ncbi:9606">patient</span>
Our previous data suggested at least partial loss of ACVR2 protein expression in a subset of primary MSS colon cancer specimens despite wild type ACVR2 polyadenine tracts [2]. We examined this further and sought to determine expression patterns of both ACVR2, ACVR1 as well as its downstream effector, pSMAD2, in 51 different primary colon cancer specimens with microsatellite stable genomic backgrounds obtained from the same cohort of the North Carolina Colon Cancer Study (NCCCS) [15], [16]. While ACVR1 receptor expression was lost in only 4% (2/51) of the patient tumor specimens (Figure 1AB, top row), loss of the primary receptor, ACVR2, occurred in 14% (7/51) (Figure 1CD, middle row). Additionally, loss of pSMAD2 expression downstream of ACVR2 and ACVR1 activation by activin occurred in 10% (5/51) of tested cases (Figure 1EF, bottom row), and was commonly observed in tumors revealing fully expressed receptors (Table 1).
###end p 17
###begin title 18
Loss of expression of three components of activin signaling in primary MSS colon cancers.
###end title 18
###begin p 19
Immunohistochemical analysis of paraffin-embedded primary colon cancers assessed expression of target protein (brown) as compared to adjacent normal tissue. A and B (Top row): ACVR1 expression is lost in a subset of MSS tumors. Example of tumor with expression in both normal and colon tumor tissue (left panel) and selective loss in a subset of tumors, but not adjacent normal colonic tissue (right panel). Overall, ACVR1 loss was observed in 2/51 or 4% of all MSS colon cancers analyzed. C and D (Middle row): ACVR2 expression is lost in a subset of MSS tumors. Two examples of selective loss of ACVR2 in colon tumor, but not normal colonic tissue (left and right panel) are shown. Overall, ACVR2 loss was observed in 7/51 or 14% of all MSS colon cancers analyzed. E and F (Bottom row): pSMAD2 expression is lost in a subset of MSS tumors. Example of expression in both normal and colon tumor tissue (left panel) and selective loss in a subset of tumors, but not normal colonic tissue (right panel). Overall, pSMAD2 loss was observed in 5/51 or 10% of all colon cancers analyzed.
###end p 19
###begin title 20
Composition of protein expression of activin signaling proteins in colon cancers with loss of expression in at least one pathway member.
###end title 20
###begin p 21
Two of the 51 tested MSS colon cancers lost ACVR1 protein expression, 7 lost ACVR2 expression, and 5 lost pSMAD2 expression. While one cancer lost expression of all three pathway components, the remaining 4 tumors with loss of pSMAD2 expression showed expression in activin's primary receptors, while maintaining expression of total SMAD2 and TGFBR2, indicative that loss of pSMAD2 may be a separate primary event. The remaining 39 primary MSS colon cancers revealed no loss of activin signaling components.
###end p 21
###begin p 22
###xml 127 134 127 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 127 134 127 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t001"><bold>Table 1</bold></xref>
###xml 134 136 134 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, </bold>
###xml 136 144 136 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 136 144 136 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g002"><bold>Figure 2</bold></xref>
All specimens with loss of at least one activin receptor pathway component revealed expression of both total SMAD2 and TGFBR2 (Table 1, Figure 2). These data suggest that ACVR2 protein loss has the greatest prevalence among MSS tumors, followed by pSMAD2 loss, and then by ACVR1 loss. ACVR2 loss and pSMAD2 loss appear to occur in complementary subgroups, suggesting more than one target to inactivating activin signaling in MSS colon cancers. Conversely, all MSS colon cancer specimens with activin signaling component loss expressed TGFBR2.
###end p 22
###begin title 23
Summary of ACVR2 loss and its mechanisms in primary MSS colon cancer specimens.
###end title 23
###begin p 24
###xml 181 188 181 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t001">Table 1</xref>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR1</italic>
Of the 51 MSS colon cancers from the NCCCS cohort tested for ACVR2 and ACVR1 loss, 8 revealed loss of either receptor (7 lost ACVR2 and 2 lost ACVR1 with one tumor losing both, see Table 1). Of those 8, 1 lost pSMAD2. Of the 7 tumors with ACVR2 loss, 3 revealed LOH and 3 had selective ACVR2 promoter hypermethylation, while no mutations were found in any of the three kinase domain hotspots or the coding polyadenine tract of exon 10, commonly mutated in MSI colon tumors. Neither of the 2 tumors with ACVR1 loss revealed LOH at the ACVR1 locus. Conversely, of the 43 tumors expressing both ACVR2 and ACVR1, 4 or 9% lost pSMAD2 expression, while maintaining total SMAD2 and TGFBR2 expression, underscoring loss of SMAD2 phosphorylation capability as an additional primary event to disrupt activin signaling.
###end p 24
###begin title 25
LOH, but Not Mutation, Is Associated with Loss of ACVR2 Expression in Primary MSS Colon Cancer Specimens
###end title 25
###begin p 26
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR1</italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 469 477 469 477 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 469 477 469 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g002"><bold>Figure 2</bold></xref>
###xml 548 553 548 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR1</italic>
###xml 831 838 831 838 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 831 838 831 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t002"><bold>Table 2</bold></xref>
###xml 918 925 918 925 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 918 925 918 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t002"><bold>Table 2</bold></xref>
###xml 690 697 <span type="species:ncbi:9606">patient</span>
To assess whether loss of receptor expression was due to loss of heterozygosity (LOH), a common genomic mechanism of tumor suppressor inactivation in MSS colon cancers, we assayed for LOH at the ACVR2 and ACVR1 gene loci. Of the 51 MSS tumors assayed, 4 revealed allelic loss. LOH at ACVR2 was strongly associated with loss of ACVR2 protein expression (p = 0.006, Fisher's exact test), and 3/7 (43%) of MSS tumors with loss of ACVR2 protein expression also showed LOH (Figure 2), compared with 1/44 ACVR2 expressing tumors. No LOH was found at the ACVR1 locus in either ACVR1 expressing or non-expressing tumors. For further ACVR2 expression correlation with LOH, we extended the number of patient tumors from 51 to 77 samples, which revealed 5 additional tumors with ACVR2 protein loss, bringing the total number to 12/77 or 16% (Table 2). In this expanded group, 6/12 (50%) of MSS tumors with ACVR2 loss showed LOH (Table 2).
###end p 26
###begin title 27
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
Mechanisms of ACVR2 inactivation.
###end title 27
###begin p 28
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
In the 12 total cancers with ACVR2 inactivation, 6 tumors revealed additional LOH at the ACVR2 site, associated with CIN and 3 tumors revealed ACVR2 promoter hypermethylation associated with LOH-/MSI- phenotype. No mutations in the kinase domain hotspots or coding polyadenine tract of ACVR2 were found, implicating a combination of LOH and ACVR2 promoter hypermethylation in ACVR2 expression loss. For three tumors, no mechanism for loss of ACVR2 expression was identified.
###end p 28
###begin p 29
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Grady1">[4]</xref>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
We then sequenced the coding microsatellite as well as 3 separate hot spots in the kinase domain of ACVR2 (akin to corresponding mutations within TGFBR2 in MSS tumors)[4]. It should be noted that the exon 10 A8 tract in ACVR2 lies in the kinase domain of this receptor, and frameshift mutations as well as other mutations in the kinase domain abolish the phosphorylating capacity of ACVR2. However, we found no tumor specific mutations corresponding with loss of ACVR2 protein expression. These data suggest that other inactivating mechanisms play a role in the loss of ACVR2 expression.
###end p 29
###begin title 30
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
ACVR2 Promoter Hypermethylation Is Associated with Loss of ACVR2 Expression in Primary MSS Colon Cancer Specimens
###end title 30
###begin p 31
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 694 703 694 703 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 694 703 694 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3A</bold></xref>
###xml 764 773 764 773 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 764 773 764 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3B</bold></xref>
###xml 1050 1055 1050 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
To study whether epigenetic changes are associated with ACVR2 expression loss, we assessed whether the ACVR2 promoter was hypermethylated in colon cancer tissue as compared to normal and if so, whether a specific methylation pattern of ACVR2 correlated with ACVR2 protein loss in primary MSS colon cancer specimens. We initially divided the ACVR2 promoter into three regions, region 1 (+142 to -603), region 2 (-607 to -958), and region 3 (-958 to -1484). Our bisulfite sequencing results showed that there was no methylation in region 1 and minimal methylation in region 2, but the 46 CpG dinucleotides between to -958 to -1484 nucleotides relative to the transcription start site (region 3) (Figure 3A) were methylated in both cell lines and clinical specimens (Figure 3B), but not corresponding adjacent normal tissue (data not shown). Due to the difficulty in amplification of larger amplicons from paraffin embedded tissue DNA, we performed methylation specific bisulfite sequencing of a slightly smaller region (-603 to -1297 positions) of the ACVR2 promoter in the clinical specimens.
###end p 31
###begin title 32
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
ACVR2 promoter hypermethylation and LOH in colon cancer specimens and the MSS HT29 cell line and correlation of ACVR2 promoter hypermethylation and loss of ACVR2 expression.
###end title 32
###begin p 33
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 1193 1198 1181 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 1299 1306 1287 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t003">Table 3</xref>
###xml 1482 1487 1470 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 1535 1540 1523 1528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
A) ACVR2 promoter with map of positioning of MSP primers B) Using a CpG islands search program, we identified the CpG islands within the ACVR2 promoter based upon following stringent criteria: approximatelyCG percentage>55%; observed CpG/expected CpG >0.65; length >500 bp. All CpG dinucleotide sequences are represented by vertical bars across the horizontal line depicting the promoter sequence. Each circle in the bottom panel illustrates an individual CpG site corresponding to the vertical bars depicted in the upper panel. Based upon bisulfite sequencing, each CpG site was scored quantitatively as 100% methylated (dark circles), >50% methylated (dark grey circles), <50% methylated (light grey circles) or unmethylated (white circles). As indicated, 3 of 7 ACVR2-negative CRCs demonstrated complete methylation of the critical region of ACVR2 promoter, while none of the ACVR2-expressing tumors showed any evidence for high degree/complete methylation of ACVR2 promoter. A methylation pattern similar to that seen in ACVR2 negative colon cancers was observed in the MSS colon cancer cell line HT29 with genomic DNA from HT-29 allowing for sequencing of a slightly larger region of the ACVR2 promoter. C) Six colon cancer cell lines with different microsatellite instability backgrounds (see Table 3) were analyzed for ACVR2 protein expression using immunoprecipitation techniques. Two cell lines, HCT116 (an MSI colon cancer cell line with biallelic frameshift mutations in ACVR2) and the MSS colon cancer cell line HT29 (with ACVR2 promoter hypermethylation), revealed loss of ACVR2 protein expression. D) Loss of ACVR2 protein expression correlated with decrease in ACVR2 mRNA transcription via quantitative PCR in HT29 cells when compared to the ACVR2 expressing cell line FET using GAPDH for standardization. This experiment was performed three times in triplicates, and the bar graph represents one experiment with * indicating a statistically significant difference with a p<0.001. E) ACVR2 protein expression was re-established following demethylation treatment with 5'Aza.
###end p 33
###begin p 34
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 426 433 426 433 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 426 433 426 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t002"><bold>Table 2</bold></xref>
###xml 435 444 435 444 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 435 444 435 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3B</bold></xref>
###xml 883 892 883 892 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 883 892 883 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3B</bold></xref>
In the ACVR2 non-expressing primary colon cancers from the original sample size of 51 MSS tumors, 3/7 cancers demonstrated complete methylation (100% methylated alleles) within region 3 of the ACVR2 promoter, while none of the 13 ACVR2 expressing primary colon cancers tissues assayed showed complete ACVR2 methylation, supporting a causative role for methylation and lack of ACVR2 expression (p = 0.03, Fisher's exact test) (Table 2, Figure 3B). Bisulfite sequencing results were consistent with the MSP observations (data not shown), where 3/7 ACVR2-negative CRCs showed the presence of specifically methylated alleles. Although low levels of methylation (<50% methylated alleles) were also found in 7/13 of the ACVR2-expressing CRCs, none of the CRCs demonstrated complete methylation of any CpG dinucleotides, which was consistent with enabling ACVR2 expression in these tumors (Figure 3B).
###end p 34
###begin title 35
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
ACVR2 Promoter Hypermethylation Correlates with ACVR2 Transcription and Protein Expression in Colon Cancer Cell Lines
###end title 35
###begin p 36
###xml 52 60 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 348 353 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 439 442 439 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 497 502 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 505 506 505 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 511 512 511 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 587 596 587 596 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3C</bold>
###xml 587 596 587 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3C</bold></xref>
###xml 596 601 596 601 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and </bold>
###xml 601 608 601 608 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 601 608 601 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t003"><bold>Table 3</bold></xref>
To corroborate our findings from clinical specimens in vitro, we assessed mechanisms of ACVR2 loss in colon cancer cells lines based on microsatellite instability. We tested 3 MSI-H and 3 MSS colon cancer cell lines for: 1) mutation in the coding polyadenine tract of exon 10 of ACVR2, 2) ACVR2 promoter hypermethylation, 3) quantitative RT-PCR of ACVR2 mRNA, and 4) ACVR2 protein expression by immunoprecipitation. As previously reported [2], [12], biallelic mutation in the polyadenine tract of ACVR2 (A8 to A7) in the MSI-H colon cancer cell line HCT116 causes loss of ACVR2 protein (Figure 3C and Table 3).
###end p 36
###begin title 37
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
ACVR2 expression and mechanisms for loss of expression in colon cancer cell lines.
###end title 37
###begin p 38
###xml 103 104 103 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 249 250 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 255 256 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 539 544 <span type="species:ncbi:9606">human</span>
Using colon cancers cells with different microsatellite instability backgrounds, we confirm wild type A8 exon 10 polyadenine tract in all MSS colon cancer cell lines. As previously published, the MSI colon cancer cell line HTC116 harbors biallelic A8 to A7 frameshifts, leading to loss of full length ACVR2 protein [12]. Two MSI cell lines, SW48 and RKO, harbor mono-allelic mutations with no effect on ACVR2 gene expression. The MSS colon cancer cell line HT29 revealed full ACVR2 promoter hypermethylation, akin to ACVR2 loss in primary human tumors, and was associated with loss of ACVR2 mRNA and protein.
###end p 38
###begin p 39
###xml 123 132 123 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3C</bold>
###xml 123 132 123 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3C</bold></xref>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 244 251 244 251 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 244 251 244 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t003"><bold>Table 3</bold></xref>
###xml 259 260 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 403 421 403 421 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3C, D and E</bold>
###xml 403 421 403 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3C, D and E</bold></xref>
###xml 502 507 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 607 616 607 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 607 616 607 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3B</bold></xref>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 769 774 769 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 855 870 855 870 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3D and E</bold>
###xml 855 870 855 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008308-g003"><bold>Figure 3D and E</bold></xref>
In the MSI-H cell lines SW48 and RKO, ACVR2 protein is present, as it is in the MSS colon cancer cell lines CaCo2 and FET (Figure 3C). Both RKO and SW48 contain a heterozygous mutation at ACVR2, revealing wildtype A8 as well as mutant alleles (Table 3). The A8ACVR2 allele allows the expression of ACVR2 protein. The MSS colon cancer cell line HT29 expresses decreased levels of ACVR2 mRNA and protein (Figure 3C, D and E), unlike its MSS counterparts CaCo2 and FET, neither of which harbor any exonic ACVR2 mutation (data not shown). HT29 cells revealed a distinct ACVR2 promoter hypermethylation pattern (Figure 3B) in association with mRNA and protein loss, suggesting that this specific methylation pattern causes the loss of ACVR2 expression. Demethylation of the ACVR2 promoter with 5-Aza led to re-established expression of ACVR2 mRNA and protein (Figure 3D and E). We performed an additional screen of 11 colon cancer cell lines with either MSI (DLD1, HCA7, HCT15, LoVo, LS174, SNU175, SNU407), or MSS (SNU81, SNU503, SW480, and T84) backgrounds revealing similar levels of ACVR2 mRNA and establishing HT29 as the only observed MSS colon cancer model with distinct ACVR2 loss.
###end p 39
###begin p 40
###xml 152 159 152 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 152 159 152 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t002"><bold>Table 2</bold></xref>
###xml 264 271 264 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t004">Table 4</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung3">[14]</xref>
###xml 466 473 466 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t004">Table 4</xref>
###xml 657 661 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung3">[14]</xref>
To correlate ACVR2 expression with tumor size, grade and stage, we analyzed the expanded group of 77 tumors, which contained 12 tumors with ACVR2 loss (Table 2). Of those, 69 had data on gender and race, 46 on tumor volume, 59 on tumor stage, and 65 on grade (see Table 4) allowing subanalyses. Akin to MSI-H colon cancers [14], loss of ACVR2 expression correlated with larger tumors (p = 0.024), while stage was unaffected when compared to ACVR2-expressing tumors (Table 4). This parallels our previous finding in MSI-H colon cancers, where loss of ACVR2 protein was associated with larger, more poorly differentiated tumors in a stage-independent fashion [14].
###end p 40
###begin title 41
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
Loss of ACVR2 expression is associated with larger tumor volume.
###end title 41
###begin p 42
ACVR2-expressing and non-expressing cancers were assessed for correlation of ACVR2 status with age, gender, race, tumor volume, stage and a grade. * p<0.05.
###end p 42
###begin p 43
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 199 206 199 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t002">Table 2</xref>
We then performed genomic subtype analysis of all ACVR2 non-expressing cancers and found that the lack of the chromosomal instability (CIN) phenotype correlated with ACVR2 promoter hypermethylation (Table 2), suggesting separate pathways for MSI-/LOH+ and MSI-/LOH- colon cancers.
###end p 43
###begin p 44
Taken together, these data suggest that the clinico-pathologic effects of ACVR2 protein loss may be similar in both MSI and MSS colorectal cancers despite differing underlying mechanisms of loss, implicating ACVR2 loss as an important step in colon carcinogenesis.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Mori1">[10]</xref>
###xml 170 173 170 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 262 265 262 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 569 574 569 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
Disruption of activin signaling is common in MSI-H colon cancer cell lines through mutation of ACVR2 in one of its polyadenine tracts [10], causing loss of ACVR2 protein [2]. Loss of ACVR2 protein expression was also noted in a small subset of MSS colon cancers [2]. Here, we assessed the occurrence and mechanism of disrupted activin signaling in MSS colon cancers and demonstrate that activin signaling is targeted for disruption at multiple levels in MSS colon tumors. Most commonly, ACVR2 expression is lost via a combination of LOH and epigenetic silencing of the ACVR2 promoter. These findings underscore the importance of abrogated activin signaling in colon tumorigenesis, as its disruption occurs in both MSI and MSS subtypes of colon cancer by differing distinct mechanisms.
###end p 46
###begin p 47
###xml 115 118 112 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 120 124 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Grady2">[17]</xref>
###xml 206 210 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 212 216 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Munoz1">[18]</xref>
###xml 381 386 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 391 397 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 436 439 430 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
In MSI-H colon cancers, both TGFbeta and activin are abrogated due to frameshift mutations in the type II receptor [2], [17]. The loss of both of these signaling pathways may be beneficial for tumor growth [12], [18]. Both TGFbeta and activin use the same intracellular SMAD proteins (SMAD 2 and 3) to transmit their signal. We previously observed greater than 50% overlap between ACVR2 and TGFBR2 mutations in primary MSI colon tumors [2], possibly because of additive effects in mediating the growth response, which are currently under investigation.
###end p 47
###begin p 48
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung3">[14]</xref>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Grady2">[17]</xref>
It appears that in MSI colon cancers ACVR2 mutations may occur early in tumorigenesis and are associated with increased local growth [14]. In MSS colon cancers, loss of ACVR2 correlated with larger tumors, consistent with disruption of activin-induced growth suppression. The timing of ACVR2 mutations in MSI colon cancer may be similar to that of TGFBR2 in which the frameshift mutations occur in high grade dysplasia at the interface to malignancy [17].
###end p 48
###begin p 49
###xml 411 418 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008308-t002">Table 2</xref>
We show that in MSS colon cancers at least three members of the activin signaling cascade, ACVR2, ACVR1, and pSMAD2 are disrupted. A significant subset of colon tumors displayed a decrease in phosphorylated SMAD with intact ACVR2 and TGFBR2, indicating a separate primary event downstream of the primary receptors. One case of loss of ACVR1, ACVR2 and pSMAD2 was identified, which was TGFBR2 staining positive (Table 2). This could be due to primary inactivation of pSMAD2 and separate targeting of both activin receptors, or an IHC positive truncated TGFBR2, leading pSMAD2 loss. The effect of loss of multiple targets of the same signaling cascade still needs to be carefully explored and suggests distinct functions of each member.
###end p 49
###begin p 50
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Olaru1">[19]</xref>
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung3">[14]</xref>
We detected LOH at the ACVR2 locus in 6% of MSS colon tumors, increasing to 50% in tumors with loss of ACVR2 protein expression. This overall rate is slightly lower than the frequency of ACVR2 LOH reported previously in a cohort with unknown ACVR2 status [19], although we have previously observed cohort-dependent frequencies for ACVR2 expression that may be stage or race-dependent [14].
###end p 50
###begin p 51
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 126 129 126 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Grady1">[4]</xref>
Our mutational analysis focused on hotspots akin to those implicated in inactivation of the TGFBR2 kinase domain inactivation [4], but we did not find any tumor-associated mutations when sequencing all exons in ACVR2 expressing and non-expressing colon cancer cell lines. It is possible that mutations outside of the hotspots may contribute to loss of ACVR2 in primary colon cancer specimens, although in light of the evidence for LOH as well as epigenetic silencing, this is likely to be a less important tumorigenic mechanism. However, it may play a role in the three tumors with loss of ACVR2 where we found no genetic or epigenetic mechanism directly explaining that loss.
###end p 51
###begin p 52
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hMLH1</italic>
###xml 646 650 646 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Deng1">[20]</xref>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hMLH1</italic>
###xml 1019 1024 1019 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 1285 1290 1285 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
This is the first report describing ACVR2 loss in MSS colon cancers and ACVR2 promoter hypermethylation as a mechanism, and contrasts with the mechanisms of ACVR2 loss in the MSI colon cancer cells [12]. In both primary MSS colon tumors and in HT29 colon cancer cells, the region of promoter hypermethylation that is associated with loss of ACVR2 expression is between nucleotides -1297 to -958. Among genes that are targets for epigenetic silencing, hMLH1 is the best studied for methylation, and it has been proposed that the promoter region adjacent to the transcription start site (TSS) is critical for transcriptional silencing of this gene [20]. There is lack of similar data for most other genes, but hMLH1 promoter region data is often used as a paradigm, and it is believed that for most genes, analysis of a similar promoter region is critical to correlate DNA methylation findings with loss of gene expression. In this study, we have analyzed >1500 bp proximal to the TSS, and found good correlation between ACVR2 promoter methylation (in regions -958 to -1297) and loss of protein expression by IHC. Our data suggests that instead of mere proximity to the TSS, differential access to methylation co-activators or repressors in a promoter determines gene silencing, and for ACVR2 such a region may occur upwards of 900 bp from the TSS.
###end p 52
###begin p 53
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-SatiaAbouta1">[15]</xref>
###xml 866 871 866 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 917 922 917 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 1033 1038 1033 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 1508 1513 1508 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 1584 1589 1584 1589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 1693 1700 <span type="species:ncbi:9606">patient</span>
We are mindful that the total number of MSS patients with ACVR2 loss that were investigated in this study is not large, underscoring that this is a relatively infrequent event [15]. We did not intend to determine the overall frequencies of such events, but to show an alternative mechanism of ACVR2 protein loss in MSS colon cancers. Of 51 primary, population-based MSS tumor samples, 7 showed loss of ACVR2 expression. In keeping with the 51 subjects being randomly drawn from the cohort, between 7% and 21% of MSS tumors in the population should show similar loss of ACVR2 expression with 95% confidence (Clopper-Pearson exact confidence interval). Increasing the sample size to 77 revealed loss of ACVR2 in 12/77 or 16% and a statistically significant correlation of loss of ACVR2 with increased tumor size. Further, genomic subtype analysis revealed that LOH at ACVR2 was associated with the CIN phenotype, while ACVR2 hypermethylation correlated with the CIMP phenotype. While these categorizations allow attribution of loss of ACVR2 expression to promoter hypermethylation and/or chromosomal instability as a mechanism in MSS cancers, alternative mechanisms such as histone modification and/or microRNAs may be at play, particularly in the LOH negative/methylation negative cancers. Our data however, show a significant correlation between loss of ACVR2 expression and LOH/epigenetic silencing. Thus we provide evidence for the existence of either chromosomal instability or epigenetic modification of ACVR2 in colon cancer and identify a cell model for epigenetic silencing of ACVR2. The full clinical impact of this data will require further confirmation in future studies with larger patient samples.
###end p 53
###begin p 54
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
In conclusion, loss of ACVR2, ACVR1 and pSMAD2 expression occurs in a subset of MSS tumors, and the evidence supports that this results in abrogation of the normal growth suppressive activity of activin signaling. Decreased pSMAD2 is commonly associated with wild type ACVR2 and ACVR1. Mechanisms for ACVR2 loss include LOH at ACVR2 and ACVR2 promoter hypermethylation between nucleotides -1297 and -958, which are associated with CIN and CIMP phenotypes, respectively. Loss of ACVR2 is associated with increased tumor size. Therefore, activin signaling can be inactivated by distinctive mechanisms in MSI and MSS colon cancers, suggesting the importance of this pathway in controlling colonocyte growth.
###end p 54
###begin title 55
Materials and Methods
###end title 55
###begin title 56
Ethics Statement
###end title 56
###begin p 57
###xml 203 211 <span type="species:ncbi:9606">patients</span>
This study was conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by the Institutional Review Board of the University of North Carolina hospitals. All patients provided written informed consent for the collection of samples as part of the under IRB approval as part of the North Carolina Colorectal Cancer Study (NCCCS) see below. Analysis as part of this study was completely de-identified and no identifying information was available to the PI, making this study exempt from a separate consent.
###end p 57
###begin title 58
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Samples
###end title 58
###begin p 59
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-SatiaAbouta1">[15]</xref>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Satia1">[16]</xref>
###xml 300 303 300 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 394 401 <span type="species:ncbi:9606">patient</span>
Sporadic colon tumors were prospectively collected under IRB approval as part of the North Carolina Colorectal Cancer Study (NCCCS), a population-based, case-control study comprising 503 patients [15], [16]. Microsatellite analysis was performed from paraffin-embedded tissue as previously described [2], segregating the cohort into 54 MSI-H, and 449 MSS/MSI-L patients. For this study, 51 MSS patient samples with ample tumor and normal tissue were randomly selected.
###end p 59
###begin title 60
Cell Lines
###end title 60
###begin p 61
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Gong1">[21]</xref>
The MSI colon cancer cells lines HCT116, SW48, DLD1, HCA7, HCT15, LoVo, LS174T, SNU175, SNU407, SW48, and RKO, as well as the MSS colon cancer cell lines CaCo2, HT29, SNU81, SNU503, SW480, and T84 were maintained in Iscove's Modified Dulbecco's Medium (Invitrogen Corporation, Carlsbad, CA) and FET were maintained in F12/Dulbeco's Modified Eagles Medium at conditions previously described [12]. All cell lines are available from ATCC except for FET (kind gift of Michael Brattain, Medical College of Ohio, Toledo, OH) [21].
###end p 61
###begin title 62
Tissue Microdissection, DNA Extraction, and RNA Extraction
###end title 62
###begin p 63
DNA from the formalin-fixed, paraffin-embedded material was extracted following microdissection using the Takara DEXPAT kit (Takara Bio Inc., Japan). Genomic DNA from cells lines was obtained using QIAamp DNA mini kit (Qiagen, Valencia, CA). RNA from cell lines was obtained using the TRIzol reagent (Life Technologies Inc. Carlsbad, CA).
###end p 63
###begin title 64
Antibodies
###end title 64
###begin p 65
###xml 259 262 259 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 270 276 <span type="species:ncbi:9986">rabbit</span>
Rabbit anti-TyrGly mACVR2 (482-494) (generous gift from W. Vale, Salk Institute), with its target epitope in the C-terminus region of ACVR2 (beyond the resulting truncation from frameshift in exon 10) was used for immunohistochemistry as previously described [2], [12]; rabbit anti-TyrGly ACVR1 (474-494) was used at 1:800; pSMAD2 (Cell Signaling) at 1:250; total SMAD2 (Epitomics) at 1:400; and TGBR2-C16 (Santa Cruz) at 1:300.
###end p 65
###begin title 66
Immunohistochemistry for ACVR1, ACVR2, pSMAD2, TGFBR2 and SMAD2 Protein Expression
###end title 66
###begin p 67
###xml 59 62 59 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
Immunohistochemistry was performed as described previously [2]. Staining was grouped into loss or 0 (absence or significant decrease as compared to adjacent normal tissue), reduced or 1+ (subtle decrease as compared to adjacent normal tissue), unchanged or 2+ (no change as compared to adjacent normal tissue), and increased or 3+ (increase as compared to adjacent normal tissue). Three independent investigators blindly scored all slides. All three investigators had to be in agreement for a tumor to be called 0 or loss of expression.
###end p 67
###begin title 68
Loss of Heterozygosity (LOH) Analysis
###end title 68
###begin p 69
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR1</italic>
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Carethers2">[22]</xref>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Olaru1">[19]</xref>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR1</italic>
###xml 222 230 222 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref>
###xml 222 230 222 230 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref></bold>
Assessment of LOH at the ACVR2 and ACVR1 loci was performed as previously described [22] utilizing 2 microsatellite markers (D2S1353 and D2S1399) flanking ACVR2[19] as well as an intragenic marker for ACVR1 (D2S2686) (see Table S1).
###end p 69
###begin title 70
CIN Analysis
###end title 70
###begin p 71
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Shin1">[23]</xref>
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref>
###xml 285 293 285 293 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref></bold>
Analysis for CIN was performed as previously described [23]. Briefly, forward oligonucleotide primers were fluorescent-labeled with FAM at the 5'end (Applied Biosystems) and a set of 6 polymorphic microsatellite markers (D5S346, D5S409 D17S261 D17S250 D18S81, D18S91, and D18S69) (see Table S1) was used to determine LOH at chromosome 5q, 17q and 18q. PCR amplifications were performed on genomic DNA templates from both tumor and corresponding normal tissues. The amplified fluorescent PCR products were electrophoresed on an ABI PRISM 3100 Avant Genetic analyzer and analyzed by GeneMapper fragment analysis software (Applied Biosystems). When comparing the signal intensities of individual markers in tumor DNA with that of the corresponding normal DNA, a reduction of at least 40% in the signal intensity was considered indicative of LOH.
###end p 71
###begin title 72
Bisulfite Modification, Methylation Specific PCR (MSP) and Bisulfite Sequencing
###end title 72
###begin p 73
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Herman1">[24]</xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
DNA from matched colon cancer tissues and corresponding normal mucosa from CRC patients as well as DNA from colon cancer cell lines underwent bisulfite modification as described previously [24].
###end p 73
###begin p 74
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 430 438 430 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref>
###xml 430 438 430 438 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref></bold>
For methylation analysis, we first identified the tentative CpG islands in the promoter region of the ACVR2 gene based upon mapping analysis using CpG island search program (). Accordingly, we designed multiple primer sets for MSP and bisulfite sequencing that spanned the entire ACVR2 promoter region, including part of exon 1, to determine methylation density across all CpG dinucleotides with methylation specific primers (see Table S1). Bisulfite sequencing was initially performed on colon cancer cell lines as it allowed amplification of larger amplicons, and helped determine critical regions of promoter methylation that were subsequently PCR amplified in the clinical samples.
###end p 74
###begin title 75
ACVR2 Genotyping
###end title 75
###begin p 76
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 65 69 65 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Hanks1">[25]</xref>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 136 139 136 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Grady1">[4]</xref>
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 201 204 201 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 249 257 249 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref>
###xml 249 257 249 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref></bold>
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung1">[2]</xref>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 476 484 476 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref>
###xml 476 484 476 484 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref></bold>
Three hotspots in conserved regions of the kinase domain of ACVR2[25], homologous to the previously identified point mutations in TGFBR2[4] as well as the coding A8 microsatellites of ACVR2 in exon 10 [2], were amplified using specific primers (see Table S1) and followed by sequencing as previously described [2]. All exons of ACVR2 were amplified from genomic DNA extracted from select ACVR2 expressing and non-expressing colon cancer cell lines using specific primers (see Table S1) and subjected to sequencing using the DNA Sequencing Shared Resource, UCSD Cancer Center. Any new mutations were to be deposited to GenBank.
###end p 76
###begin title 77
Quantitative Expression of ACVR2 mRNA
###end title 77
###begin p 78
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACVR2</italic>
###xml 495 499 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
###xml 580 588 574 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref>
###xml 580 588 574 582 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0008308.s001">Table S1</xref></bold>
###xml 1076 1107 1066 1097 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CATGTTCGTCATGGGTGTGAACCA-3&#8242;</named-content>
###xml 1109 1139 1099 1129 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGTGATGGCATGGACTGTGGTCAT-3&#8242;</named-content>
To detect the amplification of ACVR2 in colon cancer cells, we performed a quantitative polymerase-chain reaction. Briefly, all 17 colon cancer cell lines were grown to 60% confluence. RNA was extracted using a Trizol-based protocol. The concentration of RNA dissolved in DEPC-treated water was assessed using a Beckman-Coulter DU640B spectrophotometer (Beckman-Coulter, Fullerton, CA). We performed RT-PCR using an oligo dT for incubation at 37degreesC to generate cDNA as previously described [12]. Then, quantitative PCR was carried out using specific primers for exon 10 (see Table S1) Templates from each cell line were prepared in triplicate per target gene as 10 microL reactions (40 ng template, 2X Mesa Green qPCR MasterMix for SYBR assay, 100X forward and reverse primers). Templates were plated on fast optical 96-well plate (Applied Biosystems, Foster City, CA) and spun for 2 minutes at 2000 rpm. Results were observed and analyzed on the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA). GAPDH mRNA amplification was performed in parallel (5'- CATGTTCGTCATGGGTGTGAACCA-3', 5'-AGTGATGGCATGGACTGTGGTCAT-3') to obtain a normalized ACVR2-GAPDH after the relative expression of each gene was calculated using standard curves.
###end p 78
###begin title 79
Immunoprecipitation (IP)
###end title 79
###begin p 80
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008308-Jung2">[12]</xref>
To detect presence of ACVR2 in the colon cancer cell lines, we performed immunoprecipitation with ACVR2 followed by Western blotting as previously described [12]. Then, a subset of HT29 cells was either treated with the demethylating agent 5-Aza (Sigma) for 72 hours or vehicle prior to lysis and assessment of ACVR2 expression.
###end p 80
###begin title 81
Statistical Analysis
###end title 81
###begin p 82
Analysis was performed with the help of the UCSD Moores Cancer Center Biostatistics Core (K.M.) applying Fisher's exact test and Student's t-test with a p value of <0.05 indicating statistical significance. Further, Clopper-Pearson exact confidence interval was used to determine the 95% confidence interval.
###end p 82
###begin title 83
Supporting Information
###end title 83
###begin p 84
Specific primers used in LOH analysis, ACVR2 genotyping as well as ACVR2 promoter bisulfite sequencing. F denotes forward primer, R denotes reverse primer; U denotes unmethylated and M methylated.
###end p 84
###begin p 85
(0.09 MB DOC)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
We thank Betty L. Cabrera for assistance in editing.
###end p 87
###begin title 88
References
###end title 88
###begin article-title 89
Biology of Colorectal Carcinoma. , editors. .
###end article-title 89
###begin article-title 90
Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers.
###end article-title 90
###begin article-title 91
###xml 61 66 <span type="species:ncbi:9606">human</span>
Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair.
###end article-title 91
###begin article-title 92
Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.
###end article-title 92
###begin article-title 93
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.
###end article-title 93
###begin article-title 94
DPC4 gene in various tumor types.
###end article-title 94
###begin article-title 95
###xml 40 45 <span type="species:ncbi:9606">human</span>
Somatic alterations of the DPC4 gene in human colorectal cancers in vivo.
###end article-title 95
###begin article-title 96
Regulation of cell proliferation, apoptosis, and carcinogenesis by activin.
###end article-title 96
###begin article-title 97
Generation of activin receptor type IIB isoform-specific hypomorphic alleles.
###end article-title 97
###begin article-title 98
Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability.
###end article-title 98
###begin article-title 99
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
###end article-title 99
###begin article-title 100
Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.
###end article-title 100
###begin article-title 101
Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
###end article-title 101
###begin article-title 102
Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers.
###end article-title 102
###begin article-title 103
Associations of micronutrients with Colon Cancer risk in African Americans and whites: results from the North Carolina Colon Cancer Study.
###end article-title 103
###begin article-title 104
Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study.
###end article-title 104
###begin article-title 105
###xml 106 111 <span type="species:ncbi:9606">human</span>
Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
###end article-title 105
###begin article-title 106
Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
###end article-title 106
###begin article-title 107
###xml 75 80 <span type="species:ncbi:9606">human</span>
Loss of heterozygosity and mutational analyses of the ACTRII gene locus in human colorectal tumors.
###end article-title 107
###begin article-title 108
Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.
###end article-title 108
###begin article-title 109
###xml 120 125 <span type="species:ncbi:9606">human</span>
Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
###end article-title 109
###begin article-title 110
Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.
###end article-title 110
###begin article-title 111
###xml 74 79 <span type="species:ncbi:9606">human</span>
Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer.
###end article-title 111
###begin article-title 112
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
###end article-title 112
###begin article-title 113
The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.
###end article-title 113
###begin p 114
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 114
###begin p 115
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Supported by the UCSD Academic Senate to B.J., the U.S. Public Health Service DK074019 to B.J.; DK067287, the VA Research Service, and the American Cancer Society Institutional Research Grant #70-002 to J.M.C., and the UCSD Digestive Diseases Research Development Center (DK080506). DNA sequencing was performed by the DNA Sequencing Shared Resource, UCSD Cancer Center, which is funded in part by NCI Cancer Center Support Grant # 2 P30 CA023100-23. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 115

